This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Dermatology				
Dermatitis	Signal transducer and activator of transcription 5 (STAT5); Janus kinase-2 (JAK-2)	<p>Human tissue and mouse studies suggest inhibiting STAT5 could help treat atopic dermatitis. In patient tissue samples, numbers of mast cells with activated STAT5 were higher in skin lesions than in normal skin. In mouse models of atopic dermatitis, mast cell-specific deletion of <i>Stat5</i> decreased disease severity compared with <i>Stat5</i> expression. Also in the models, a JAK-2 inhibitor that blocked Stat5 activation decreased both levels of infiltrating mast cells into skin lesions and disease severity compared with vehicle. Planned work includes additional testing of JAK-2 inhibitors in the models.</p> <p>Jakafi, a JAK-1 and JAK-2 inhibitor from Incyte Corp. and Novartis AG, is approved to treat myeloproliferative disorder.</p> <p>At least 10 companies have JAK-2 inhibitors in preclinical or clinical development for multiple indications.</p> <p>SciBX 7(5); doi:10.1038/scibx.2014.144 Published online Feb. 6, 2014</p>	Unpatented; unlicensed; available for partnering	<p>Ando, T. <i>et al. Cell Rep.</i>; published online Jan. 9, 2014; doi:10.1016/j.celrep.2013.12.029 Contact: Toshiaki Kawakami, La Jolla Institute for Allergy & Immunology, La Jolla, Calif. e-mail: toshi@liji.org</p>